T-SPOT.TB

Oxford Immunotec Ltd. 

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology*. Their proprietary T-SPOT technology platform allows the measurement of the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.
 
The T-SPOT.TB test, is used to test for latent Tuberculosis (TB) infection, or LTBI. The T-SPOT.TB test has been included in clinical guidelines (that is, guidelines issued by governmental agencies and professional societies covering recommended or suggested uses of available diagnostics) for TB screening in 17 countries, including the United States, several European countries and Japan. Click here for more information on the T-SPOT.TB test.
 
*Oxford Immunotec Ltd. is a publicly traded company listed in the United States on the NASDAQ stock exchange (NASDAQ:OXFD).